Physicians' Academy for Cardiovascular Education

Pioglitazone: where do we stand in 2011?

3' education - Dec. 1, 2011

Prof. John Betteridge (UCL, London) gives an update on recent developments with pioglitazone.
Based on preclinical studies, pioglitazone seems to increase the risk of bladder cancer, prof. Betteridge tells. Also in the PROactive trial, that he was involved in, a slight excess of bladder cancer was found. However, a recent epidemiology study showed no statistical increase in bladder cancer. A French study with a similar population led to the drug being withdrawn in France.
The EMA made an announcement, saying that there does seem to be a small increased risk of bladder cancer, but the risk-benefit is maintained for the drug in certain populations of diabetic patients. “That is very encouraging”, Betteridge adds. “There are issues in terms of how you adjust potential biases from these epidemiological studies.”

About the speaker

Professor Betteridge is Professor Emeritus of Endocrinology and Metabolism, Department of Medicine, University College London. He is also a Consultant Physician, University College Hospitals Foundation Trust, London, UK. Professor Betteridge is a past Chairman of HEART UK and past President of the Council on Lipids in Clinical Medicine at The Royal Society of Medicine. He is Associate Dean of the Royal Society of Medicine. He is a “Distinguished Fellow of the International Atherosclerosis Society”. He is a Fellow of the American Heart Association and a member of numerous international bodies, including the European and American Diabetes Associations and the European Atherosclerosis Society. He is co-chair of the executive committee of CARDS, a major primary CVD prevention trial with atorvastatin in type 2 diabetes. He is the UK Principal Investigator and member of the International Steering Committee for PROactive a major secondary prevention trial with pioglitazone in type 2 diabetes. He is a member of the Joint European Society of Cardiology and European Association for the Study of Diabetes taskforce group on Diabetes and Vascular Disease and was a member of the Medical Research Council Steering Committee for the UKPDS. He served on the British Heart Foundation Grants Committee 2005-2009.
Professor Betteridge’s main clinical interests are in the care of patients with diabetes mellitus and patients with lipid disorders. His main research interests relate to the pathogenesis of atherosclerosis, and in particular the role of lipoprotein metabolism. He has authored over 300 publications in peer-reviewed journals. His books include Lipoproteins in Health and Disease (Edward Arnold, 1999), Diabetes: Current Perspectives (Martin Dunitz, 2000), Lipids and Vascular Disease (Martin Dunitz, 2000), Case Studies in Diabetes (Martin Dunitz, 2003), Lipids and Coronary Heart Disease (Arnold, 2003) and Case Studies in Lipid Management (Informa Healthcare ) 2006.
Professor Betteridge is a director at the educational board of the Physicians’ Academy for Cardiovascular education (PACE foundation).

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: